	٦			THE COLUMN TO THE COLUMN THE COLU				
FORM F	TO-139	0 (Modified) U.S. DEPARTMENT OF COM	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER				
(1	TF	RANSMITTAL LETTER	PU4828USW					
		DESIGNATED/ELECTI	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR					
			G UNDER 35 U.S.C. 371	10/516577				
INTE		IONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
]	PCT/US03/17347	June 3, 2003	June 4, 2002				
		NVENTION	I Al I I I I I I I I I I I I I I I I I I	,				
Phar	mace	eutical Compositions Compri	sing Abacavir and Lamivudine					
		T(S) FOR DO/EO/US , Robin; GOODSON, Gary, V	Novno					
CUK	KIE,	, Rubin, GOODSON, Gary,	vayne					
A12	41	ith automite to the United Ste	tes Designated/Elected Office (DO/EO/US) th	o following items and other information:				
1.	Ø		tems concerning a filing under 35 U.S.C. 371.					
2.		_	UENT submission of items concerning a filin					
3.	×	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.						
4.			expiration of 19 months from the priority date	(Article 31).				
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))						
		a. is attached hereto (requ	ired only if not communicated by the Interna	tional Bureau).				
		b. has been communicated	by the International Bureau.					
		c. 🛮 is not required, as the a	pplication was filed in the United States Rece	iving Office (RO/US).				
6.		An English language translation	of the International Application as filed (35 U	I.S.C. 371(c)(2)).				
		a. is attached hereto.	·					
			omitted under 35 U.S.C. 154(d)(4).					
7.	\boxtimes		International Application under PCT Article					
			uired only if not communicated by the Interna	ational Bureau).				
			ed by the International Bureau.					
			wever, the time limit for making such amend	ments has NOT expired.				
_	_	d. Me have not been made and						
8.	⋈	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9. 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT						
	_	Article 36 (35 U.S.C. 371 (c)(5))						
11.	×	A copy of the International Preliminary Examination Report (PCT/IPEA/409).						
12.	×	A copy of the International Search Report (PCT/ISA/210).						
	_	3 to 20 below concern documen						
13.			ement under 37 CFR 1.97 and 1.98.					
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
15. 16.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.						
10. 17.		A substitute specification.						
18.		A change of power of attorney and/or address letter.						
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).						
21.			guage translation of the international applicat					
22.	\boxtimes	• •	332063787 US					
23.	×	Other items or information:	:					
		a) PCT Cover Page b) PCT Request						

PCTUS1/REV03

	ON NO. (IF KNOWN, SEE 37 CFR	ATTORNEY'S DOCKET NUMBER							
4	10/5165//		PU4828USW						
24. The	following fees are submitted:.				CALCULATION	S PTO USE ONLY			
BASIC NATION	NAL FEE (37 CFR 1.492 (a) (1) - ((5)):							
internation	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO								
USPTO b	nal preliminary examination fee (37 out International Search Report prepare	\$920.00							
but intern	nal preliminary examination fee (37 ational search fee (37 CFR 1.445(a)	(2)) paid to USPTO	TO 	\$770.00					
but all cla	nal preliminary examination fee (37 ims did not satisfy provisions of PC	T Article 33(1)-(4)		\$730.00					
Internation and all cla	nal preliminary examination fee (37 aims satisfied provisions of PCT Art ENTER APPROPRI	ticle 33(1)-(4)		\$100.00					
		30	\$920.00						
	0.00 for furnishing the oath or declar earliest claimed priority date (37 C			ATE	\$0.00				
CLAIMS	NUMBER FILED	NUMBER EXTRA		18.00	\$72.00				
Total claims	24 - 20 =	2	<u> </u>	36.00	\$172.00				
Independent clair				30.00	\$0.00				
Multiple Depend	ent Claims (check if applicable).	ABOVE CALCULA			\$1,164.00				
- Annlinent el	laims small entity status. See 37 CF			, –	\$1,104.00				
Applicant control					\$0.00				
		SU	BTOTA	L =	\$1,164.00				
Processing fee of months from the	\$130.00 for furnishing the English earliest claimed priority date (37 C	translation later than	20 E	□ 30 +	\$0.00				
		TOTAL NATIONA	AL FEE	: =	\$1,164.00				
Fee for recording accompanied by a	the enclosed assignment (37 CFR an appropriate cover sheet (37 CFR	.21(h)). The assignment mus 3.28, 3.31) (check if applica	st be able).		\$0.00				
		TOTAL FEES ENC	CLOSEI) =	\$1,164.00				
		<u>-</u>	_		Amount to be: refunded	\$			
					charged	\$			
a. 🗆 A	check in the amount of	to cover the above f	fees is encl	osed.					
c. 🔀 T									
d. 🔲 F									
NOTE: Where:	an appropriate time limit under 3'	7 CFR 1.494 or 1.495 has no	t been me						
1.137(a) or (b)) i 	must be filed and granted to restor	re the application to pending	g status.	1					
SEND ALL COR	RESPONDENCE TO:		4		14	,			
		ļ,	SIGN	ATURE	L. Mu				
				MICKE					
			Kare	n L. Pru	ıs				
			NAM	Е					
71	3347		39,33	37					
	JJTI		REGI	STRATIC	ON NUMBER				
İ			عائه	2.	1. 1 1/	2 2/m/			
i			<u>///</u> Ď4Ti	<i>eren E</i>	201 X, 20				
			DAI	_					

10/516577

CERTIFICATE OF I		S MAIL" (37 CFR 1.10)05 Rec'	d PCT/Ppgke()N2. DEC 2004 PU4828USW				
Serial No. Filing Date To Be Assigned Concurrently Herew		Examiner	Group Art Unit				
nvention: Pharmaceuti	cal Compositions Comprising	Abacavir and Lamivudine					
I hereby certify that the	e following correspondence:						
National Phase Applica	ation with accompanying pape	ers					
		type of correspondence)					
CFR 1.10 in an envel	th the United States Postal Scope addressed to: Commission (Date)	ervice "Express Mail Post Office to A oner for Patents, P.O. Box 1450, Ale: –	ddressee" service under 37 xandria, VA 22313-1450 on				
		Valerie L. Phil	llips				
	(Typed or Printed Name of Person Mailing Correspondence)						
	Valerie L. Millin						
	-	EV332063	Torresnondence)				
	_	("Express Mail" Mailing Lo	<u> </u>				
		(Espress state of					